References
- Adachi M, Volk BW. (1977). Gaucher disease in mice induced by conduritol-B-epoxide: morphologic features. Arch Pathol Lab Med 101:255–9
- Arafa HM. (2009). Possible contribution of beta-glucosidase and caspases in the cytotoxicity of glufosfamide in colon cancer cells. Eur J Pharmacol 616:58–63
- Aureli M, Masilamani AP, Illuzzi G, et al. (2009). Activity of plasma membrane beta-galactosidase and beta-glucosidase. FEBS Lett 583:2469–73
- Baldissera VD, de Mattos AA, Coral GP, et al. (2012). Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Ann Hepatol 11:899–906
- Cao C, Liu T, Zhu H, et al. (2014). Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review. Clin Lymphoma Myeloma Leuk 14:e145–50
- Chahine LM, Qiang J, Ashbridge E, et al. (2013). Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol 70:852–8
- Dinur T, Osiecki KM, Legler G, et al. (1986). Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site. Proc Natl Acad Sci USA 83:1660–4
- Ferlay J, Soerjomataram I, Dikshit R, et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–86
- Finn RS, Zhu AX. (2009). Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 9:503–9
- Forner A, Bruix J. (2012). Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol 13:750–1
- Forner A, Llovet JM, Bruix J. (2012). Hepatocellular carcinoma. Lancet 379:1245–55
- Futerman AH, Hannun YA. (2004). The complex life of simple sphingolipids. EMBO Rep 5:777–82
- Futerman AH, van Meer G. (2004). The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5:554–65
- Futerman AH, Sussman JL, Horowitz M, et al. (2004). New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 25:147–51
- Gao Q, Zhao YJ, Wang XY, et al. (2012). CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res 72:3546–56
- Grabowski GA, Osiecki-Newman K, Dinur T, et al. (1986). Human acid beta-glucosidase. Use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes. J Biol Chem 261:8263–9
- Hara A, Radin NS. (1979). Destruction and resynthesis of mouse beta-glucosidases. Biochim Biophys Acta 582:412–22
- Hoshida Y, Villanueva A, Kobayashi M, et al. (2008). Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995–2004
- Kitatani K, Sheldon K, Anelli V, et al. (2009). Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid. J Biol Chem 284:12979–88
- Kitatani K, Sheldon K, Rajagopalan V, et al. (2009). Involvement of acid beta-glucosidase 1 in the salvage pathway of ceramide formation. J Biol Chem 284:12972–8
- Li Y, Sekine T, Funayama M, et al. (2014). Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease. Neurobiol Aging 35:935 e3–8
- Llovet JM, Bru C, Bruix J. (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–38
- Llovet JM, Ricci S, Mazzaferro V, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–90
- Parkin DM, Bray F, Ferlay J, et al. (2005). Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
- Sun Y, Zhang W, Xu YH, et al. (2013). Substrate compositional variation with tissue/region and Gba1 mutations in mouse models-implications for Gaucher disease. PLoS One 8:e57560
- Torre LA, Bray F, Siegel RL, et al. (2015). Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
- Xu Y, Liu L, Liu J, et al. (2011). A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128:412–17